Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes

Diabetic Medicine

Volumn 26, Issue 6, 2009, Pages 649-654

  Cuthbertson, J ^a   Patterson, S ^b   O'Harte, F P M ^b   Bell, P M ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Dipeptidylpeptidase 4; Glucagon like peptide 1; Metformin; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; METFORMIN; PLACEBO;

AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; EATING; FASTING; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED;

EID: 66449129517     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2009.02748.x     Document Type: Article

References (23)

1. Abraham E, Leech CA, Lin JC, Zulewski H, Habener JF. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology 2002 143 : 3152 3161. (Pubitemid 34809888)
2. Larsson H, Holst JJ, Ahern B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand 1997 160 : 413 422. (Pubitemid 27342031)
3. Dupre J, Behme MT, Hramiak IM, McFarlane P, Williamson MP, Zabel P et al. Glucagon-like peptide-1 reduces postprandial glycaemic excursions in IDDM. Diabetes 1995 44 : 626 630.
4. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (non-insulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996 81 : 327 332.
5. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002 359 : 824 883.
6. Lankas GR, Leiting B, Roy RS. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005 54 : 2988 2994. (Pubitemid 41401097)
7. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type 2 diabetic patients and in healthy subjects. Diabetes 1995 44 : 1126 1131.
8. Mentlein R. Dipeptidyl-peptidase IV CD26 - role in the inactivation of regulatory peptides. Regul Pept 1999 85 : 9 24. (Pubitemid 29505281)
9. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E et al. Effects of metformin on glucagon-like peptide-1 (GLP-1) and leptin levels in obese non-diabetic subjects. Diabetes Care 2001 24 : 489 494. (Pubitemid 32198418)
10. Lindsay J, Duffy NA, McKillop M, Ardill J, O'Harte FPM, Flatt P et al. Inhibition of dipeptidyl peptidase IV (DPP-4) activity by oral metformin in Type 2 diabetes. Diabet Med 2005 22 : 654 657. (Pubitemid 40593146)
11. Yasuda N, Inoue T, Nagakura T, Yamazaki K, Kira K, Saeki T et al. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun 2002 298 : 779 784. (Pubitemid 35356808)
12. Hinke SA, McIntosh CHS, Hoffmann T, Kühn-Wache K, Wagner L, Bär J et al. On combination therapy of diabetes with metformin and dipeptidyl peptidase IV inhibitors. Diabetes Care 2002 25 : 1490 1491.
13. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for initiation and adjustment of therapy. Diabetologia 2006 49 : 1711 1721.
14. Basu R, Shah P, Basu A, Norby B, Dicke B, Chandramouli V et al. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes. Diabetes 2008 57 : 24 31.
15. Kim YD, Park K-G, Lee Y-S, Park Y-Y, Kim D-K, Nedumaran B et al. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 2008 57 : 306 314.
16. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996 334 : 574 579. (Pubitemid 126537875)
17. Wiernsperger N, Rapin JR. Metformin-insulin interactions: from organ to cell. Diabetes Metab Rev 1995 11 : S3 S12.
18. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995 333 : 550 554.
19. Green B, Duffy NA, Irwin N, Gault VA, O'Harte FPM, Flatt PR. Inhibition of dipeptidyl peptidase IV (DPPIV) activity by metformin enhances the anti-diabetic effects of glucagon-like peptide-1 (GLP-1). Eur J Pharmacol 2006 547 : 192 199. (Pubitemid 44373906)
20. Sambol NC, Brookes LG, Chiang J, Goodman AM, Lin ET, Liu CY et al. Food intake and dosage level, but not tablet vs. solution dosage form, affect the absorption of metformin HC1 in man. Br J Pharmacol 1996 42 : 510 515.
21. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M et al. Pharmacokinetics and pharmacodynamics of single doses of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects. Clin Pharmacol Ther 2005 78 : 675 688.
22. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. J Am Med Assoc 2007 298 : 194 206. (Pubitemid 47057766)
23. Jackson RA, Hawa MI, Jaspan JB, Sim BM, DiSilvio L, Featherbe D et al. Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes 1987 36 : 632 640. (Pubitemid 18024740)